Embed Size (px)
Citation preview
WORLD’S LEADING SEASONAL INFLUENZA VACCINE MANUFACTURER
• The Swiftwater site, today owned by Sanofi Pasteur and formerly the Pocono Biological Laboratories foundedin 1897, created its first influenza vaccine in 1947.
• After doubling its global vaccine production capacity in the past 10 years, Sanofi Pasteur now produces morethan 220 million doses of seasonal influenza vaccine for worldwide distribution.
• Sanofi Pasteur provides approximately 40% of the global influenza vaccine supply and at least 65 milliondoses for the United States.
• Sanofi Pasteur continues to discover and deliver a variety of influenza vaccine improvements. Ourinnovations include:
o The first intradermal influenza vaccine for adults 18-64 years of age,
o The first high-dose influenza vaccine for adults aged 65 and over,
o Quadrivalent influenza vaccines to help provide broad protection against influenza by containingtwo A strains and two B strains.
• Sanofi Pasteur is actively exploring several leading universal influenza vaccine developments through bothinternal and external collaborations.
• Sanofi Pasteur’s Swiftwater campus is designed and built to standards that allow Sanofi Pasteur to switchfrom production of seasonal influenza vaccine to pandemic influenza vaccine.
PROVIDING VACCINES TO MEET GLOBAL PUBLIC HEALTH NEEDS
• Sanofi Pasteur has played a critical role in responding to the changing needs of public health by developing innovative products such as combination pediatric vaccines, meningococcal meningitis vaccines and novel influenza vaccines.
ONE OF THE WORLD’S LARGEST SITES DEDICATED TO THE RESEARCH, DEVELOPMENTAND PRODUCTION OF VACCINES
CAMPUS SERVES AS THE U.S. HEADQUARTERS FOR SANOFI PASTEUR
COM 11626 June 2016
SWIFTWATER, PA
• The Swiftwater site produces, fills, formulates, inspects and/or packages vaccines for seven diseases: influenza, pertussis, diphtheria, meningitis, Haemophilus influenzae type b (Hib) infections, tetanus and yellow fever.
• In addition to its licensed products, Sanofi Pasteur is investing in a number of Research and Development projects, including vaccine candidates, to help prevent dengue fever and symptomatic Clostridium difficile infection.
SITE GROWTH CONTINUES WITH INVESTMENTS IN EXCESS OF $1.3 BILLION
• Since 2001, the Swiftwater site has made a number ofinvestments to support the changing needs of publichealth. The more recent projects include:
o Construction of a new Formulation, Filling andLyophilization facility to manufacture yellow fevervaccine and the dengue fever vaccine1 began in 2014.
o Construction began in 2015 of a Quality Control facilityto provide testing capabilities for allproducts manufactured on site.
o Construction for the new Global Clinical Immunologyfacility featuring bio-safety level laboratory space broke ground in 2015.
A HISTORIC CAMPUS
• The Swiftwater site was founded in 1897 by Dr. Richard Sleeas the Pocono Biological Laboratories.
• The laboratories later became part of the National Drug Company, then Connaught Laboratories, followed by Pasteur Mérieux Connaught and Aventis Pasteur.
• Located in the scenic Pocono Mountains, Pennsylvania, thesite has nearly 120 years of vaccine experience.
• The now 500-plus acre campus has more than 50 buildings and is a global center of scientific and industrialexpertise.
• Swiftwater has a dedicated workforce of more than 2,500 people in Industrial Operations, R&D, Commercial Operations and various Support Functions.
CONTACT:US Media RelationsMarisol PeronT. (570)[email protected]
COM 11626 June 2016
1 As of March 15, 2016, the dengue fever vaccine candidate has been licensed in Mexico, the Philippines, Brazil and El Salvador.
